BIOMAT Database Logo BIOMAT Database Logo

Bone marrow erythroid precursor Ca++ regulates the response to human recombinant erythropoietin (rHuEPO) in hemodialysis patients. 1990

S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.

The modulation of erythropoiesis by erythropoietin is conditioned by the concentration of Ca++ in the cytoplasm of the bone marrow erythroid precursors. We evaluated in vitro erythroid colony development from bone marrow erythroid precursors incubated with increasing concentrations of Ca++ or Ca++ plus 1,25 (OH)2 D3, and bone marrow erythroid precursor cytoplasmic Ca++ concentrations in 10 anemic hemodialysis (HD) patients before and during rHuEPO therapy. Results showed that: a) in vitro: in uremics patients before rHuEPO therapy, bone marrow erythroid precursor cytoplasmic Ca++ was lower than in normal subjects; the addition of Ca++ to the bone marrow erythroid precursors induced a dose-dependent Ca++ and erythroid colony development increase; 1,25 (OH)2 D3 potentiated this effect; b) in vivo: rHuEPO normalized bone marrow erythroid precursor Ca++ and erythroid colony development. An inverse correlation was seen between bone marrow erythroid colony development, precursor CA++ before therapy, the in vitro erythroid and the rHuEPO dose needed in vivo to normalize hematological parameters. These data emphasize the role of Ca++ in erythropoiesis and may aid understanding of the mode of action of rHuEPO in HD.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004920 Erythropoiesis The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction. Erythropoieses
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).
July 2009, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
January 1992, Haematologica,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
November 1991, Clinical nephrology,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
January 1993, Haematologica,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
January 1996, Haematologica,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
[Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
May 1990, Revista clinica espanola,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
August 1995, The Journal of the Association of Physicians of India,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
November 1994, Nihon Jinzo Gakkai shi,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
June 1990, Clinical nephrology,
S Carozzi, and A Ramello, and M G Nasini, and C Schelotto, and P M Caviglia, and A Cantaluppi, and M Salit, and S Lamperi
Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
November 1989, Kidney international,
Copied contents to your clipboard!